- Record: found
- Abstract: found
- Article: found
Increases in Levels of Collagen Types I and IV Messenger Ribonucleic Acid in Murine Kidneys after Treatment with Ciclosporin
11 December 2008
Ciclosporin, Interstitial damage, Collagen type I and IV, Murine kidney
Abstract
We investigated changes in the levels of mRNA transcripts encoding types I and IV collagen in the kidney following the administration of ciclosporin (CS) in mice. Daily doses of CS increased the levels of mRNAs encoding collagen types I and IV in whole kidneys harvested 4 weeks after treatment. At this time point, neither a reduction of renal function detected by serum creatinine, nor histologic evidence of interstitial damage were present. Elevated levels of serum creatinine as well as mild interstitial changes did develop, however, 12 weeks after daily treatment with CS. Collagen type I transcripts were almost normal after 12 weeks, whereas levels of type IV mRNA were still elevated. Our findings indicate that increases in transcripts encoding collagens precede a deterioration in renal function and the development of interstitial changes in this murine model of chronic CS nephrotoxicity.
Related collections
Author and article information
Journal
Affiliations
Article
186710 Nephron 1992;60:87–91Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.